NantHealth Inc (NASDAQ:NH) COO Ronald Allen Louks sold 5,604 shares of the stock in a transaction dated Wednesday, June 6th. The shares were sold at an average price of $3.49, for a total value of $19,557.96. Following the completion of the transaction, the chief operating officer now directly owns 177,391 shares in the company, valued at $619,094.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ronald Allen Louks also recently made the following trade(s):

  • On Sunday, May 6th, Ronald Allen Louks sold 7,005 shares of NantHealth stock. The stock was sold at an average price of $3.41, for a total value of $23,887.05.
  • On Friday, April 6th, Ronald Allen Louks sold 7,005 shares of NantHealth stock. The stock was sold at an average price of $3.04, for a total value of $21,295.20.

Shares of NantHealth traded up $0.10, hitting $3.28, during midday trading on Thursday, according to Marketbeat. 33,400 shares of the stock were exchanged, compared to its average volume of 99,933. NantHealth Inc has a 52-week low of $2.60 and a 52-week high of $5.26. The firm has a market cap of $349.67 million, a P/E ratio of -2.92 and a beta of 0.23. The company has a quick ratio of 1.88, a current ratio of 1.90 and a debt-to-equity ratio of 1.15.

NantHealth (NASDAQ:NH) last released its earnings results on Wednesday, March 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The company had revenue of $22.30 million during the quarter, compared to analysts’ expectations of $23.50 million. NantHealth had a negative net margin of 168.84% and a negative return on equity of 63.06%. sell-side analysts expect that NantHealth Inc will post -0.61 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Deutsche Bank AG lifted its holdings in NantHealth by 117.4% during the 4th quarter. Deutsche Bank AG now owns 45,610 shares of the company’s stock worth $137,000 after buying an additional 24,635 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of NantHealth during the fourth quarter worth about $103,000. SG Americas Securities LLC increased its position in shares of NantHealth by 157.6% during the fourth quarter. SG Americas Securities LLC now owns 72,521 shares of the company’s stock worth $221,000 after purchasing an additional 44,372 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of NantHealth during the third quarter worth about $365,000. Finally, Millennium Management LLC acquired a new stake in shares of NantHealth during the fourth quarter worth about $344,000. 5.59% of the stock is owned by institutional investors.

A number of brokerages have issued reports on NH. Cowen reiterated a “buy” rating and set a $4.50 price target on shares of NantHealth in a research report on Tuesday, March 20th. Jefferies Financial Group set a $5.00 target price on NantHealth and gave the company a “buy” rating in a research report on Wednesday, March 21st. BidaskClub upgraded NantHealth from a “hold” rating to a “buy” rating in a research report on Wednesday, May 9th. Finally, ValuEngine upgraded NantHealth from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. NantHealth presently has a consensus rating of “Buy” and a consensus target price of $4.69.

About NantHealth

NantHealth, Inc, together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care.

Insider Buying and Selling by Quarter for NantHealth (NASDAQ:NH)

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.